Last edition
News about "Temab-A monotherapy"
US FDA Grants AbbVie's Telisotuzumab 2 Breakthrough Designations
The US FDA has granted AbbVie’s Temab-A 2 Breakthrough Therapy Designations (BTDs) for CRC and NSCLC, advancing its c-Met-directed ADC development in solid tumors.
Temab-A Monotherapy | 08/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members